Vaccine yielded encouraging long-term survival rates in certain patients with NSCLCApril 04, 2012
"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.
These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.
For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.
Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.
In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.
Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.
American Association for Cancer Research
Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles
Restoring ability to halt cell division may protect lung cells from cancer
Researchers led by a team at the University of Illinois at Chicago, have identified a novel role for a signaling mechanism in lung cells that permanently places them into a state of suspended animation called senescence.
Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor (EGFR) mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology.
Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC
A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel.
Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
Health economics helps insurers, health care systems and providers make treatment decisions based on the cost of extra "units" of health arising from a specific treatment.
Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
Moffitt researchers develop novel approach to visualize, measure protein complexes in tumors
Cancer diagnosis and treatment decisions are often hampered by a lack of knowledge of the biological processes occurring within the tumor.
Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
More evidence for impact of lung cancer targeted therapy from trial
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Immune checkpoint inhibitors may work in brain cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
Three drugs may be better than one for certain patients with advanced colorectal cancer
Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles